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Abstract We hypothesize that diabetes-induced impaired
collateral formation after a hindlimb ligation in rats is in part
caused by intracellular glycation and that overexpression
of glyoxalase-I (GLO-I), i.e. the major detoxifying en-
zyme for advanced-glycation-endproduct (AGE) precur-
sors, can prevent this. Wild-type and GLO-I transgenic
rats with or without diabetes (induced by 55 mg/kg
streptozotocin) were subjected to ligation of the right
femoral artery. Laser Doppler perfusion imaging showed
a significantly decreased blood perfusion recovery after
6 days in the diabetic animals compared with control
animals, without any effect of Glo1 overexpression.
In vivo time-of-flight magnetic resonance angiography
at 7-Tesla showed a significant decrease in the number and
volume of collaterals in the wild-type diabetic animals com-
pared with the control animals. Glo1 overexpression
partially prevented this decrease in the diabetic animals.
Diabetes-induced impairment of arteriogenic adaptation
can be partially rescued by overexpressing of GLO-I,
indicating a role of AGEs in diabetes-induced impaired col-
lateral formation.
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Introduction
Arterial occlusive lesions caused by atherosclerosis lead to
cardiovascular and peripheral arterial diseases and are the
leading causes of death in modern society [1]. In the presence
of arterial occlusions, the fate of the affected organ is not only
related to the severity of the occlusion, but also by the capa-
bility of the developing collateral vessel system to compensate
blood perfusion loss. This development of new vessels is sig-
nificantly reduced in patients with diabetes [2]. Therefore,
patients with diabetes suffer from both more arterial occlusion
and less compensatory collateral capacity, leading to more
foot ulcerations and lower extremity amputations than in
non-diabetic patients [1].
Hyperglycaemia is the initiating cause of diabetic tissue
damage, and there are several mechanisms that mediate these
effects [3]. One of the possible mechanisms is the production
of advanced glycation endproducts (AGE) or their reactive
precursors. AGEs are formed from reducing sugars reacting
non-enzymatically with amino groups in proteins through a
so-called Maillard reaction, resulting in dysfunctional modi-
fied-products. The major sources of intracellular
glycation are the glycolytic intermediates, methylglyoxal
(MGO) and glyoxal (GO). Under physiological circumstances
these reactive oxo-aldehydes can be efficiently detoxified by
the glyoxalase system, in which the enzyme glyoxalase-I
(GLO-I) is the rate-limiting step [4].
Previous research showed that elevated levels of MGO in
cultured endothelial cells cause cell detachment, anoikis and
impaired tube formation [5], which could be prevented by
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GLO-I overexpression [6]. Furthermore, Liu et al. have exten-
sively shown in vitro that MGO also impairs endothelial cell
viability, migration, tube formation, autophagy, and angiogene-
sis in ex vivo aortic rings, which could be rescued by overex-
pression ofGlo1 [7]. However, despite these in vitro studies and
the recent finding that Glo1 overexpression restores ischaemia-
induced angiogenesis in diabetic mice as measured by laser
Doppler, [8], the in vivo effect of GLO-1 overexpression on
specifically collateral formation is unknown. We therefore used
magnetic resonance angiography in a diabetic Glo1 overex-
pressing rat hindlimb ligation model to investigate if diabetes-
induced impaired collateral formation could be prevented.
Materials and methods
Diabetic hindlimb ischemic model in rats
This study was approved by the Maastricht University animal
ethics committee. Wild-type and GLO-I transgenic rats which
were non-diabetic (WtC and TgC respectively) or diabetic
(WtD and TgD respectively) for a period of 12 weeks
(55 mg/kg streptozotocin) were subjected to ligation of the
right femoral artery (n = 10 per group). The femoral artery
was occluded by placing ligations 0.5 cm below the branch of
the circumflex femoral artery and just above the bifurcation of
the popliteal and saphenous artery. During the ligation proce-
dure, the Laser Doppler perfusion imaging (LDPI) and mag-
netic resonance angiography (MRA) exams, rats were venti-
lated with 3 % isoflurane in oxygen. The animals received
Temgesic® (Schering-Plough BV, 0.01 mg/kg subcutaneous-
ly) as postoperative medication.
Laser Doppler perfusion imaging
LDPI (Moor Instruments Ltd., Devon, UK) was used to mea-
sure hindlimb blood flow after ligation. Before measuring
perfusion, animals were anesthetized and placed on a warming
pad to ensure constant body temperature. A low-intensity laser
light beam (λ = 632.8 nm) scanned the surface of the skin
without contact at a standardized working distance. Scan
modus was set at 10 ms/pixel and resolution at 256 × 256
pixels. Three scans were completed per time point for each
animal for both the ischaemic and non-ischaemic limbs and
average perfusion in arbitrary units (flux) was determined


































































Fig. 1 Diabetes impairs recovery
of peripheral blood flow after
hindlimb ligation without any
effects of Glo1 overexpression.
Blood perfusion in the paw was
measured with LDPI in wild-type
control (WtC), transgenic control
(TgC), wild-type diabetic (WtD)
and transgenic diabetic (TgD) rats
before (Pre) and after (Post)
ligation of the right femoral artery,
and on day 3 and day 6 after
ligation a. Recovery was
quantified by determining the
perfusion ratio between the
ischaemic and the non-ischaemic
paw b. or by perfusion percentage
with the perfusion before
the ligation set on
100 % c. * indicates a p-value
<0.05 when comparing
WtC with WtD
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was normalized to the contra-lateral non-ischaemic limb to
minimize variation due to ambient light and temperature.
Baseline perfusion was assessed preoperatively and postoper-
ative immediately after surgery, and after 3- and 6-days recov-
ery. The normalized perfusion was used to calculate percent-
age of baseline perfusion at the postoperative time points.
Magnetic resonance angiography and collateral
quantification
Seven days post ligation the animals were imaged in supine
position in a 7.0 Tesla MR system with a birdcage quadrature
coil (Bruker Biospin, Ettlingen, Germany) as described earlier
[9]. Briefly, the angiography protocol consisted of a multi-
slice 2D flow-compensated gradient echo sequence. A flow
saturation slab located distally to the imaging plane was ap-
plied to suppress venous enhancement.
The number of visible collateral arteries, based on
Longland definition [10] was counted in the medical image
software application OsiriX (version 3.7) using axial maxi-
mum intensity projections in the cranio-caudal direction over
a limited range of axial slices. The thickness and location of
the slab was adjusted to obtain optimal depiction of the col-
laterals. In addition, quantification of the collateralization was
assessed by signal intensity distribution analysis (for a detailed
description, see [9]) The collateral index represents the nor-
malized volume fraction of vessels with a diameter of approx-
imately 0.5 mm and is therefore used as a measure for the
volume of collateral arteries.
Statistics
All values are expressed as mean ± SEM. Statistical differ-
ences between groups were tested using one-way
ANOVAwith a post-hoc Bonferroni correction for the groups
of interest. A p-value of less than 0.05 was considered statis-
tically significant.
Results
Fasted glucose levels 12 weeks after STZ were significantly
higher in WtD animals (20.0 ± 1.5 mM) compared WtC ani-
mals (3.8 ± 0.1 mM), without effect of GLO-I overexpression
(3.5 ± 0.1, and 23.9 ± 1.3 mM for TgC and TgD animals,
respectively).
LDPI was used to measure the perfusion in the distal
area of both the ischaemic and non-ischaemic limbs
preoperatively, postoperatively and on postoperative days 3
and 6 (see Fig. 1a). Blood flow is reported for each group as
the ratio of blood flow in the ischaemic hindlimb to the non-
ischaemic hindlimb (I/NI, see Fig. 1b), and as a percentage of
the perfusion recorded at baseline (see Fig. 1c). Immediately
postoperatively, blood flow decreased to on average
22 ± 2.2 % of baseline, without any significant differences
between the groups, indicating that the hindlimb was effec-
tively and equally rendered ischaemic in all animals. There
was a significant decrease in limb blood flow, beginning on
day 3 in WtD as compared with and the WtC group for I/NI


































WtC TgC WtD TgD
Fig. 2 Glo1 overexpression
partially prevents
diabetes-induced impairment of
collateral growth after hindlimb
ligation. Collateral growth was
imaged with MRA a. and the
number b. and intensity c. of the
collaterals were quantified with
the application software OsiriX
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value. (p < 0.05) This difference continued to day 6 (p < 0.01),
without any effect by GLO-I overexpression.
Because laser Doppler measurements are restricted to the
superficial skin blood flow distal to the occlusion, we
also applied MRA to assess deep arteriogenesis at the
actual site of ligation. As measured by MRA, 7 days after
ligation (Fig. 2a), the number of collateral arteries was de-
creased inWtD compared toWtC rats (Fig. 2b). This decrease
could be partially prevented by GLO-1 overexpression. In
line, the collateral index (i.e. the collateral artery volume)
(Fig. 2c) showed comparable results between WtD versus
WtC and also an improvement in the TgD rats.
Discussion
We showed that diabetic rats with a Glo1 overexpression
displayed significantly more collateral vessels with a higher
signal intensity at the site of ligation than their wild-type dia-
betic littermates.
The mechanisms by which specifically MGO can compro-
mise collateral formation have been extensively investigated
in vitro. MGO has been shown to modify RGD and GFOGER
integrin binding sites of collagen, causing endothelial
cell detachment, anoikis, and inhibition of angiogenesis,
thereby theoretically impairing the remodeling of the
collaterals [5]. Furthermore, MGO also compromises
the binding of VEGF to VEGFR2 and thereby the an-
giogenic process [7]. We show, using a state of the art imaging
technique, that this MGO-induced collateral damage also oc-
curs in vivo.
Despite the beneficial effect of Glo1 overexpression on
collateral growth at the site of ligation as measured by
MRA, Glo1 overexpression did not improve blood flow in
the paws of the rats. After 7 days the paws of the rats showed
no signs of necrosis and the ligation did not affect movement
behavior of the rats in any group. Any differences in function-
al capacity of the hindlimb can only be addressed with a tread-
mill exercise test, which we unfortunately did not perform.
Furthermore, preservation of tissue blood flow in the distal
hypoxic part of the limb is also dependent on the process of
angiogenesis, which occurs later during recovery.
In summary, our observations show that overexpression of
Glo1 promotes collateral growth in diabetic rats in vivo. Care
should be taken when addressing collateral formation with
laser Doppler techniques. Our research suggests that
overexpression of Glo1 leads to quenching of oxo-aldehydes
and the inhibition of AGE formation as observed in earlier
studies [4, 11]. Therefore, increasing the expression of Glo1,
as recently demonstrated in an randomized, placebo-controlled
crossover clinical trial with trans-resveratrol and hesperetin,
[12], can be an important new tool to prevent diabetes-
induced impaired arteriogenesis.
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